Sebaa Sarra, Hizette Nicolas, Boucherit-Otmani Zahia, Courtois Philippe
Laboratory of Physiology and Pharmacology, Université Libre de Bruxelles, B‑1070 Brussels, Belgium.
Laboratory of Antibiotics Antifungals: Physico‑Chemistry, Synthesis and Biological Activity, University of Aboubekr Belkaïd‑Tlemcen, Tlemcen 13000, Algeria.
Mol Med Rep. 2017 Mar;15(3):1135-1142. doi: 10.3892/mmr.2017.6148. Epub 2017 Jan 25.
The present study investigated the in vitro effect of lysozyme (0-1,000 µg/ml) on Candida albicans (C. albicans) biofilm development. Investigations were conducted on C. albicans ATCC 10231 and on 10 clinical isolates from dentures. Strains were cultured aerobically at 37˚C in Sabouraud broth. Yeast growth was evaluated by turbidimetry. Biofilm biomass was quantified on a polystyrene support by crystal violet staining and on acrylic surfaces by counts of colony forming units. Lysozyme affected biofilm formation to a greater extent than it affected growth. For the ATCC 10231 reference strain, lysozyme acted as a biofilm promotor on polystyrene at the highest concentration tested (1,000 µg/ml, non‑physiological). When the reference strain was investigated on acrylic resin support, lysozyme acted as a significant biofilm promotor on rough resin, but less on smooth resin. The attached biomass in the presence of physiological concentrations of lysozyme (10‑30 µg/ml) was significantly decreased compared with the hypothetical value of 100% using a one‑sample t‑test, but a comparison between the different lysozyme conditions using analysis of variance and post hoc tests did not reveal significant differences. In 10 wild strains, different patterns of biofilm formation on polystyrene were observed in the presence of lysozyme. Some strains, characterized by large amounts of biofilm formation in the presence of 1,000 µg/ml lysozyme, were poor biofilm producers at low concentrations of lysozyme. In contrast, some strains that were poor biofilm producers with a high lysozyme concentration were more inhibited by low concentrations of lysozyme. The present study emphasizes the need to develop strategies for biofilm control based on in vitro experiments, and to implement these in clinical trials prior to approval of hygiene products enriched with exocrine proteins, such as lysozyme. Further studies will extend these investigations to other Candida species, and to fungi and bacteria present in oral biofilms.
本研究调查了溶菌酶(0 - 1000微克/毫升)对白色念珠菌生物膜形成的体外作用。对白色念珠菌ATCC 10231以及从假牙分离出的10株临床分离株进行了研究。菌株在37˚C的沙氏肉汤中需氧培养。通过比浊法评估酵母生长。生物膜生物量通过结晶紫染色在聚苯乙烯载体上进行定量,并通过菌落形成单位计数在丙烯酸表面进行定量。溶菌酶对生物膜形成的影响比对生长的影响更大。对于ATCC 10231参考菌株,在测试的最高浓度(1000微克/毫升,非生理浓度)下,溶菌酶在聚苯乙烯上作为生物膜促进剂起作用。当在丙烯酸树脂载体上研究参考菌株时,溶菌酶在粗糙树脂上作为显著的生物膜促进剂起作用,但在光滑树脂上作用较小。与使用单样本t检验得出的假设值100%相比,在生理浓度的溶菌酶(10 - 30微克/毫升)存在下附着的生物量显著降低,但使用方差分析和事后检验对不同溶菌酶条件进行比较时未发现显著差异。在10株野生菌株中,在溶菌酶存在下观察到聚苯乙烯上生物膜形成的不同模式。一些菌株在1000微克/毫升溶菌酶存在下以大量生物膜形成为特征,但在低浓度溶菌酶下是较差的生物膜产生者。相反,一些在高溶菌酶浓度下是较差生物膜产生者的菌株在低浓度溶菌酶下受到的抑制更大。本研究强调需要基于体外实验制定生物膜控制策略,并在富含外分泌蛋白(如溶菌酶)的卫生产品获批之前在临床试验中实施这些策略。进一步的研究将把这些调查扩展到其他念珠菌物种,以及口腔生物膜中存在的真菌和细菌。